Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

685
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
685
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

515
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
515
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

441
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
441
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

713
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
713
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.2K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.1K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular dissection of protein complexes isolated from sections of human brain.

bioRxiv : the preprint server for biology·2026
Same author

A shared transcriptional network in the nucleus accumbens supports resilience to chronic stress across sex.

bioRxiv : the preprint server for biology·2026
Same author

Transcriptional profiles of antidepressant resistance across the corticolimbic pathway of chronically stressed mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases.

Molecular psychiatry·2026
Same author

Targeting mGlyR with nanobodies for depression.

Nature communications·2026
Same author

Astrocytic CREB regulates transcriptomic, neuronal, and behavioral responses to cocaine.

Science advances·2025

Related Experiment Video

Updated: Dec 29, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

461

Ketamine: The final frontier or another depressing end?

Omar K Sial1, Eric M Parise2, Lyonna F Parise2

  • 1Texas A&M University: Department of Psychological and Brain Sciences, 4325 TAMU, College Station, TX, 77843, USA.

Behavioural Brain Research
|February 5, 2020
PubMed
Summary
This summary is machine-generated.

Ketamine offers rapid antidepressant effects by influencing N-methyl-d-aspartate (NMDA) receptors and other pathways. Further research is crucial to fully understand ketamine

Keywords:
Antidepressant mechanismDepressionKetamineMajor Depressive DisorderNMDANon-NMDA mechanismRapid antidepressantSpravato

More Related Videos

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
07:52

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

12.4K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K

Related Experiment Videos

Last Updated: Dec 29, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

461
Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
07:52

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

12.4K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Ketamine rapidly alleviates depression, offering a novel therapeutic approach.
  • Initial hypotheses focused on N-methyl-d-aspartate (NMDA) receptor blockade as the primary mechanism.

Purpose of the Study:

  • To review current knowledge on NMDA and non-NMDA mechanisms of ketamine's antidepressant effects.
  • To address controversies regarding ketamine's stereoisomers and metabolites.
  • To highlight the need for further research into ketamine's actions and consequences.

Main Methods:

  • Literature review of studies on ketamine's antidepressant mechanisms.
  • Analysis of research implicating various glutamate receptors (NMDA, AMPA) and neurotransmitter systems.
  • Examination of data on ketamine stereoisomers and metabolites.

Main Results:

  • Evidence suggests ketamine's antidepressant effects involve both NMDA and non-NMDA receptor pathways.
  • Other neurotransmitter systems may also contribute to ketamine's efficacy.
  • The precise roles of stereoisomers and metabolites remain under investigation.

Conclusions:

  • Ketamine's antidepressant action is complex, involving multiple neurotransmitter systems beyond NMDA receptors.
  • Understanding these diverse mechanisms is vital for optimizing ketamine-based therapies.
  • Further research is essential to fully characterize short- and long-term effects of ketamine treatments, including esketamine.